INDIA – Indian diagnostic company Mylab Discovery Solutions has launched its novel rapid antigen tests for the diagnosis of sexually transmitted diseases, namely Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Syphilis.
The development comes weeks after Thermo Fisher Scientific and Mylab Discovery Solutions partnered to design, develop and market the Applied Biosystems TaqPath PCR kits for infectious diseases across India.
Mylab also plans to launch new vitro diagnostic (IVD) medical devices and kits designed to empower small laboratories across the country.
The company has expanded its portfolio of solutions to include diagnostics for sexual health. The rapid tests are designed to deliver an accurate diagnosis and improve patient management.
In a press release, Mylab said: “HIV 1/2 Ab and HCV Ab are rapid tests for the detection of antibodies specific to HIV-1 and HIV-2 and HCV respectively, while Syphilis Antibody test detects antibodies (IgG, IgA, IgM) to Treponema Pallidum (TP) to aid in the diagnosis of Syphilis.”
The company stated that its accurate, rapid, point-of-care tests include PathoCatch HIV 1/2 Ab test, PathoCatch HIV 1/2 Ab test, PathoCatch HCV Ab test, and PathoCatch Syphilis Ab test.
The PathoCatch HIV 1/2 Ab test measures the presence of antibodies in response to the presence of HIV, providing accurate and reliable results in less than 20 minutes while the PathoCatch HCV Ab test detects antibodies generated as a response to HCV infection within 20 minutes.
The new rapid tests are easy to use, capable of being stored at room temperature, and can be deployed at the point of care in resource-limited settings.
“PathoCatch Syphilis Ab test is a rapid immunoassay, detects IgG, IgM and IgA antibodies, providing accurate results during all stages of the disease, within 20 minutes,” outlined Mylab.
The point-of-care diagnostics can also be distributed to blood banks for the effective detection of transfusion-transmissible infections (TTIs) among blood donors thus reducing their transmission.
Sexually transmitted infections (STIs) have a profound impact on sexual and reproductive health worldwide. STIs can have serious consequences beyond the immediate impact of the infection itself.
According to the World Health Organization (WHO), more than 1 million STIs are acquired every day posing a major health challenge.
Early and fast detection is the core pillar to preventing the transmission of these viral infections.
According to the company statement, rapid tests for the detection of Treponemal antibodies can facilitate earlier diagnosis, access to treatment, and linkage to care.
Mylab announced that its molecular tests for Hepatitis C, HIV, and Syphilis will be available in hospitals and laboratories in India in the coming weeks.
The novel molecular diagnostic tests for the diagnosis of sexually transmitted diseases will provide better sensitivity and specificity than traditional tests.
“We are launching three new rapid kits – HIV, HCV, and Syphilis – for detection at the point of care. We will continue to strengthen this portfolio,” Hasmukh Rawal, Managing Director (MD) & Co-founder of Mylab, reaffirmed the patients.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
